Dyne Therapeutics

Biotech

Dyne's DMD trial back on track after FDA lifts clinical hold

Dyne Therapeutics is back on track to move its first asset into the clinic in the coming weeks after the FDA lifted a clinical hold on the drug.
James Waldron Jul 5, 2022 10:00am

Sanofi-backed Expansion nabs $80M for RNA neurodegenerative work

Sep 29, 2021 7:00am

Dyne Therapeutics gunning for $100M IPO weeks after a VC raise

Aug 26, 2020 7:55am

Dyne Therapeutics grabs $115M to ramp up muscle disease pipeline

Aug 10, 2020 9:54am

Startup Dyne Therapeutics hires Kaleido exec as new chief

Oct 1, 2019 6:42am